Accession Number: | 0000899243-23-003059 |
Date: | 2023-01-27 |
Issuer: | JASPER THERAPEUTICS, INC. (JSPR) |
Original Submission Date: |
CARLYLE GROUP INC.
C/O THE CARLYLE GROUP
1001 PENNSYLVANIA AVE. NW, SUITE 220S
WASHINGTON, DC 20004-2505
ABINGWORTH LLP
38 JERMYN STREET,
LONDON, ENGLAND, X0 SW1Y 6DN
CARLYLE HOLDINGS I GP INC.
C/O THE CARLYLE GROUP
1001 PENNSYLVANIA AVE. NW, SUITE 220S
WASHINGTON, DC 20004-2505
CARLYLE HOLDINGS I GP SUB L.L.C.
C/O THE CARLYLE GROUP
1001 PENNSYLVANIA AVE. NW, SUITE 220S
WASHINGTON, DC 20004-2505
CARLYLE HOLDINGS I L.P.
C/O THE CARLYLE GROUP
1001 PENNSYLVANIA AVE. NW, SUITE 220S
WASHINGTON, DC 20004-2505
CG SUBSIDIARY HOLDINGS L.L.C.
C/O THE CARLYLE GROUP
1001 PENNSYLVANIA AVE. NW, SUITE 220S
WASHINGTON, DC 20004-2505
TC GROUP, LLC
C/O THE CARLYLE GROUP
1001 PENNSYLVANIA AVE. NW, SUITE 220S
WASHINGTON, DC 20004-2505
CARLYLE INVESTMENT MANAGEMENT LLC
C/O THE CARLYLE GROUP
1001 PENNSYLVANIA AVE. NW, SUITE 220S
WASHINGTON, DC 20004-2505
CARLYLE GENESIS UK LLC
C/O THE CARLYLE GROUP
1001 PENNSYLVANIA AVE. NW, SUITE 220S
WASHINGTON, DC 20004-2505
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
VOTING COMMON STOCK | 2023-01-27 | P | 3,133,333 | a | $1.50 | 8,761,891 | indirect |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | reflects securities held of record by abingworth bioventures vii lp ("abv vii"). abv vii has delegated to abingworth llp all investment and dispositive power over the securities held of record by abv vii. |
f2 | the carlyle group inc., which is a publicly traded entity listed on nasdaq, is the sole shareholder of carlyle holdings i gp inc., which is the sole member of carlyle holdings i gp sub l.l.c., which is the general partner of carlyle holdings i l.p., which, with respect to the securities reported herein, is the managing member of cg subsidiary holdings l.l.c., which is the managing member of tc group, l.l.c., which is the managing member of carlyle investment management, l.l.c., which is the sole member of carlyle genesis uk llc, which is the principal member of abingworth llp. accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by abv vii, but each disclaims beneficial ownership of such securities except to the extent of their pecuniary interest therein, if any. |